Items where authors include "Kendall, J."

Article

Fornacon-Wood, I., Nuamek, T., Hudson, E.M. et al. (9 more authors) (2024) Analyzing patient-reported outcome data in oncology care. International Journal of Radiation Oncology • Biology • Physics. ISSN 0360-3016

Sidhu, J.K., Siggins, M.K. orcid.org/0000-0003-2504-6518, Liew, F. orcid.org/0000-0002-8736-9198 et al. (400 more authors) (2024) Delayed mucosal antiviral responses despite robust peripheral inflammation in fatal COVID-19. The Journal of Infectious Diseases, 230 (1). e17-e29. ISSN 0022-1899

Liew, F., Efstathiou, C. orcid.org/0000-0001-6125-8126, Fontanella, S. et al. (1457 more authors) (2024) Large-scale phenotyping of patients with long COVID post-hospitalization reveals mechanistic subtypes of disease. Nature Immunology, 25 (4). pp. 607-621. ISSN 1529-2908

Michael, B.D. orcid.org/0000-0002-8693-8926, Dunai, C. orcid.org/0000-0001-5799-2387, Needham, E.J. orcid.org/0000-0001-7042-7462 et al. (559 more authors) (2023) Para-infectious brain injury in COVID-19 persists at follow-up despite attenuated cytokine and autoantibody responses. Nature Communications, 14 (1). 8487. ISSN 2041-1723

Goldswain, H., Dong, X., Penrice-Randal, R. et al. (405 more authors) (2023) The P323L substitution in the SARS-CoV-2 polymerase (NSP12) confers a selective advantage during infection. Genome Biology, 24 (1). 47. ISSN 1474-7596

Liew, F. orcid.org/0000-0002-8736-9198, Talwar, S., Cross, A. et al. (1439 more authors) (2023) SARS-CoV-2-specific nasal IgA wanes 9 months after hospitalisation with COVID-19 and is not induced by subsequent vaccination. eBioMedicine, 87. 104402. ISSN 2352-3964

Kendall, J. orcid.org/0000-0003-2884-4849, Hall, A., Roberts, S. et al. (5 more authors) (2022) MUKtwelve protocol: a phase II randomised, controlled, open, parallel group, multicentre trial of selinexor, cyclophosphamide and prednisolone (SCP) versus cyclophosphamide and prednisolone (CP) in patients with relapsed or refractory multiple myeloma. BMJ Open, 12 (10). e062504. ISSN 2044-6055

Horne, A., Brown, S., Butterworth, K. et al. (26 more authors) (2022) EP05.01-007 CONCORDE - A Phase Ib Platform Study of Novel Agents in COmbinatioN with COnventional RaDiothErapy in Non-small Cell Lung Cancer (NSCLC). Journal of Thoracic Oncology, 17 (9). s267-s268. ISSN 1556-0864

Millar, J.E., Neyton, L., Seth, S. et al. (263 more authors) (2022) Distinct clinical symptom patterns in patients hospitalised with COVID-19 in an analysis of 59,011 patients in the ISARIC-4C study. Scientific Reports, 12. 6843. ISSN 2045-2322

Coleman, R., Brown, J., Rathbone, E. et al. (9 more authors) (2020) CApecitabine plus Radium-223 (Xofigo™) in breast cancer patients with BONe metastases (CARBON) : study protocol for a phase IB/IIA randomised controlled trial. Trials, 21 (1). 89.

Wang, Z., Andrews, P. orcid.org/0000-0001-7215-4410, Kendall, J. et al. (6 more authors) (2016) SMASH, a fragmentation and sequencing method for genomic copy number analysis. Genome Research, 26 (6). pp. 844-851. ISSN 1088-9051

Conference or Workshop Item

Horne, A., Ali, A., Brown, S. et al. (28 more authors) (2022) 153 CONCORDE: a phase Ib platform study of novel agents in combination with conventional radiotherapy in non-small cell lung cancer (NSCLC). In: 20th Annual British Thoracic Oncology Group Conference 2022, 27-28 Jan 2022, Virtual.

Proceedings Paper

Greystoke, A., Oughton, J.B., Brown, S.R. et al. (16 more authors) (2024) Olaparib, AZD1390, ceralasertib, saruparib and consolidation durvalumab (CONCORDE) phase Ib platform study of novel DNA damage response inhibitor (DDRi) agents in combination with radiotherapy in non-small cell lung cancer (NSCLC). In: Journal of Clinical Oncology. 2024 ASCO Annual Meeting, 31 May - 04 Jun 2024, Chicago, USA. ASCO Publications .

Horne, A., Brown, S., Coyle, V. et al. (13 more authors) (2023) P2.01-04 An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC. In: Journal of Thoracic Oncology. 2023 World Conference on Lung Cancer, 09-12 Sep 2023, Singapore. Elsevier BV , S296-S297.

Horne, A., Brown, S., Coyle, V. et al. (13 more authors) (2023) An Update on the CONCORDE study: A Phase Ib Platform Study of Novel Agents in Combination With Conventional Radiotherapy in NSCLC. In: Journal of Thoracic Oncology. 2023 World Conference on Lung Cancer, 09-12 Sep 2023, Singapore. Elsevier , S296-S297.

Short, S. orcid.org/0000-0003-4423-7256, Kendall, J., West, E. orcid.org/0000-0001-7449-120X et al. (7 more authors) (2022) P11.64.A Long-term follow up and translational data from the ReoGlio phase Ib trial of GM-CSF and intravenous pelareorep (Reovirus) alongside standard of care in GBM. In: Neuro-Oncology. 17th Meeting of the European Association of Neuro-Oncology, 15-18 Sep 2022, Vienna, Austria. Oxford University Press , ii73-ii73.